(Q56786021)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

main subject

phase I clinical trial

0 references

immunotherapy

1 reference

head and neck squamous cell carcinoma

inferred from title

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Gabriel Victora

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

Carlos Rodrigo Zárate-Bladés

8 January 2020

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Paulo Andrade Lotufo

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Célio L Silva

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

P Michaluart

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

K A Abdallah

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

F D Lima

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

R Smith

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

V Coelho

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

A Socorro-Silva

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

E C Volsi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

A R Ferraz

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

A K Barreto

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

M C Chammas

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

R Gomes

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

E Gebrim

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

L Arakawa-Sugueno

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

K P Fernandes

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

M R Cardoso

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J Kalil

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

6 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

676-684

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/cgt.2008.35

8 January 2020

exact match

0 references

cites work

Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Evolution of patients with squamous cell carcinoma of upper aerodigestive tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Heat shock protein vaccines: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

The Group II Chaperonin TRiC Protects Proteolytic Intermediates from Degradation in the MHC Class I Antigen Processing Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

The Mycobacterium leprae hsp65 displays proteolytic activity. Mutagenesis studies indicate that the M. leprae hsp65 proteolytic activity is catalytically related to the HslVU protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Roles of heat-shock proteins in innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Heat shock proteins as vaccine adjuvants in infections and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Protection against tuberculosis by a plasmid DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Therapy of tuberculosis in mice by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Validation overview of bio-analytical methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

DNA vaccines for therapy of tuberculosis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-kDa protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

Adenoviral gene therapy in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Chaperones as part of immune networks.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Association of peptides with heat shock protein gp96 occurs in vivo and not after cell lysis

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Heat shock proteins refine the danger theory

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Gene therapy for cancer treatment: past, present and future

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.35

7 January 2021

Identifiers

DOI

10.1038/CGT.2008.35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18535616%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference